Kombo knife combined with sorafenib in liver cancer treatment: Efficacy and safety under immune function influence

Table 1 Single-factor Cox regression analysis and least absolute shrinkage and selection operator analysis Cox analysis

Gene	Univariate Cox regression analysis				LASSO Cox, Coefficient
	HR	HR 0.95L	HR 0.95H	P value
ADGRE5	1.029	1.012	1.048	1.07E-03	3.15E-05
CHPF2	1.057	1.025	1.089	3.90E-04	9.24E-03
DNAJC1	1.037	1.021	1.053	3.19E-06	0.015
NDUFAF1	0.929	0.887	0.974	1.99E-03	-0.006
PARP12	1.061	1.018	1.105	4.74E-03	3.51E-03
PPIA	1.011	1.006	1.016	3.92E-05	2.94E-03
RAMP3	0.949	0.921	0.979	7.63E-04	-0.013
SLC29A3	1.132	1.070	1.198	1.86E-05	0.049
SLC44A1	1.113	1.052	1.177	1.99E-04	0.038
VSIG4	1.021	1.007	1.034	2.22E-03	3.10E-03

HR: Hazard ratio; L: Low; H: High; LASSO: Least absolute shrinkage and selection operator analysis; SLC29A3: Solute carrier family 29 member 3; PPIA: Peptidylprolyl isomerase A.

Table 2 Details of the comparison of the efficacy of the three groups of patients, n (%)

Efficacy	Combo knife	Combo knife + sorafenib group	TACE + sorafenib
CR	1 (3.1)	1 (3.1)	0 (0.0)
PR	18 (56.3)	20 (62.5)	15 (46.9)
SD	9 (28.1)	8 (25.0)	10 (31.3)
PD	4 (12.5)	3 (9.4)	7 (21.8)
ORR	59.4	65.6	46.9
DCR	87.5	90.6	78.7

CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate; TACE: Transarterial chemoembolization.

Table 3 Comparison of objective response rate and disease control rate

		Combo knife	Combo knife + sorafenib group	TACE + sorafenib
Objective response	Yes	10	9	18
	No	8	19	10
	Total	28	28	28
		aPA-C = 0.032	bPB-C = 0.016
Disease control	Yes	22	23	15
	No	6	5	13
	Total	28	28	28
		aPA-C = 0.048	bPB-C = 0.022

^aP_A-C: P value for comparison between group A and group C.

^bP_B-C: P value for comparison between group B and group C.

TACE: Transarterial chemoembolization.